Dihexa: a striking preclinical nootropic with zero human evidence

Dihexa is one of the most aggressively-hyped compounds in the nootropic corner of the peptide world, and the gap between that hype and the human evidence is unusually wide — even by the standards of this field. The single sentence you’ll see repeated everywhere is that dihexa is “seven orders of magnitude more potent than BDNF” at building new connections between neurons. That number is real, it comes from a published laboratory assay, and it is also being asked to carry far more weight than a cell-culture measurement can bear. Here is the honest read of what dihexa is, what the science actually shows, and why the safety unknowns matter.

What it actually is

Dihexa — chemically N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — is a small molecule engineered from angiotensin IV, a fragment of the angiotensin peptide family that, in the brain, turns out to have cognitive rather than blood-pressure effects. The original angiotensin IV analogs were procognitive in animals but broke down too fast to be useful drugs. Dihexa was the product of a deliberate medicinal-chemistry effort to build a version that was metabolically stable and orally active while keeping the procognitive activity.^[1] That oral activity is part of why it escaped the “injectable research peptide” niche and became a pill-form nootropic in the gray market.

The headline claim: synaptogenesis

The famous “more potent than BDNF” line traces to work showing that dihexa and its angiotensin-IV–derived siblings promote the formation of new functional synapses in cultured hippocampal neurons, and improve performance in rodent learning-and-memory models.^[1] The comparison to brain-derived neurotrophic factor (BDNF) — one of the brain’s key growth proteins — is what makes the result sound spectacular. It is genuinely striking laboratory data. It is also exactly the kind of finding that needs to be read precisely: a potency ratio in a dish measures one effect in one assay. It is not a claim that dihexa improves human cognition seven million times more than anything else, and the original researchers did not say that.

The mechanism: HGF and the c-Met receptor

The most important mechanistic thread — and the one that should shape how you think about safety — is how the synaptogenesis is thought to happen. A key study found that the procognitive and synaptogenic effects of these angiotensin-IV–derived peptides are dependent on activation of the hepatocyte growth factor (HGF) / c-Met system: block c-Met, and the synapse-building effect disappears.^[2] Follow-on work framed the brain HGF/c-Met system itself as a potential target for Alzheimer’s disease,^[3] and a broader review placed dihexa within a class of small-molecule angiotensin-IV analogs being explored for Alzheimer’s and Parkinson’s.^[1] A 2018 systematic review of the angiotensin-IV cognition literature confirmed a consistent procognitive signal across experimental studies — while underscoring that this body of work is animal-based.^[4]

Claim vs. evidence

Laid out side by side, the pattern is the recurring one for gray-market nootropic peptides: the animal and in-vitro column is genuinely interesting, and the human column is empty.

What we do not know — and it is almost everything that matters for a person

Strip it down: dihexa has no approved indication anywhere, no human efficacy data, no established human dose, and no long-term safety profile. Products sold online are typically labeled “for research use only, not for human consumption,” which places them outside the prescription and compounding-pharmacy system entirely. That introduces the familiar gray-market hazards — unverified content, wrong dose, contamination — on top of the molecule’s own unknown safety. We cover that supply-chain problem in detail in where to get peptides safely, and the broader “biomarker story vs. outcome story” framing in what peptide therapy actually costs.

How dihexa compares to other nootropic peptides

It’s useful to place dihexa next to its better-studied cousins. Semax— another nootropic peptide that also works partly through BDNF — at least has decades of human clinical use in Russia, however small and uncontrolled those trials are. Dihexa has none of that: no human studies at all. On any honest evidence ladder, dihexa sits a full rung lower — squarely in preclinical territory — despite carrying some of the loudest marketing in the category. You can see exactly where it lands relative to the rest of the field in our peptide evidence matrix, and how the legitimately studied options stack up in our peptide therapy provider comparison.

The honest bottom line

Dihexa has a genuinely interesting preclinical story: a rationally-designed, orally-active angiotensin-IV analog that builds synapses in a dish and improves memory in rodents, apparently through the HGF/c-Met system.^[1][2] That is real science, and it is worth following. But interesting-in-rodents is not the same as proven-in-people, and dihexa has zero human clinical evidence to draw on. Add an unapproved, unregulated supply chain and a mechanism that deliberately switches on a growth-factor pathway, and the appropriate posture is clear: treat dihexa as an early-stage research compound with a striking hypothesis and an unanswered safety question — not a nootropic with an established benefit. The marketing is years ahead of the evidence.